Category : Search result: eosinophilic esophagitis

Eupraxia Reports 52-Week EoE Trial Data for EP-104GI

Eupraxia Pharmaceuticals reveals consistent 52-week data from RESOLVE trial, showing EP-104GI maintains clinical remission in eosinophilic esophagitis patients with strong safety profile.